VCYT VERACYTE, INC.

8-K Current Report

Filed: March 16, 2026

Health Care

Services-Medical Laboratories

VERACYTE, INC. (VCYT) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• New C-suite role: Dr. Kevin Haas (age 40) appointed Chief Development and Technology Officer, effective March 24, 2026
• Recruited from Myriad Genetics (MYGN) where he served as CTO since 2021, bringing deep genomics/bioinformatics expertise directly relevant to VCYT's diagnostic platform

+3 more insights

Other VERACYTE, INC. 8-K Filings

8-K Feb 25, 2026

Get deeper insights on VERACYTE, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.